Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of$ 0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 31.03%. A quarter ago, it was expected that this pharmaceutical company would post a loss of$ 0.33 per share when it actually produced a loss of $0.32, delivering a surprise of 3.03%. Over the last four quarters, ...